https://www.selleckchem.com/pr....oducts/l-kynurenine.
der age, suggesting that the benefit of PA against the worsening of COVID-19 may vary across stages of the disease. Among hospitalized patients with COVID-19, PA did not independently associate with hospital length of stay or any other clinically relevant outcomes. These findings should be interpreted as meaning that, among already hospitalized patients with more severe forms of COVID-19, being active is a potential protective factor likely outweighed by a cluster of comorbidities (e.g., type 2 diabetes, hypertension, weight excess
Like
Comment
Share
